Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study

Affiliations

• ¹ Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia.
• ² Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia; University of New South Wales, Sydney, Australia.
• ³ Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia; University of New South Wales, Sydney, Australia. Electronic address: john.frew@unsw.edu.au.